Covidien (NYSE:COV) won 510(k) clearance from the FDA for its Endo Gia surgical stapler.
The Endo Gia, which uses an advanced polymer felt material to provide additional support to fragile tissue, landed Japanese approval in late January.
“Covidien is committed to developing specialized solutions for our customers that enable better patient outcomes. This unique technology provides improved ease of use and reduced time in the operating room by eliminating extra steps, reducing procedure time and providing surgeons with an integrated, clinically validated buttress material for added security at the staple line,” chief medical officer Dr. Michael Tarnoff said in prepared remarks.
Mansfield, Mass.-based Covidien last week agreed to settle a beef with California workers who accused the medical device company of pressuring them not to take breaks.
